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S U M M A R Y
Objective: To reduce ventilator-associated infections (VARI) and improve outcomes for children.
Methods: This prospective interventional cohort study was conducted in a paediatric intensive care unit
(PICU) over three periods: pre-intervention, early post-intervention, and late post-intervention. These
children were on mechanical ventilation (MV) for 48 h.
Results: Overall, 312 children (11.9% of whom underwent tracheostomy) and 6187 ventilator-days were
assessed. There was a signiﬁcant reduction in ventilator-associated pneumonia (VAP) among
tracheostomized patients (8.16, 3.27, and 0.65 per 1000 tracheostomy ventilation-days before the
intervention, after the general bundle implementation, and after the tracheostomy intervention,
respectively). The median time from onset of MV to diagnosis of ventilator-associated tracheobronchitis
(VAT) increased from 5.5 to 48 days in the late post-intervention period (p = 0.004), and was associated
with a signiﬁcant increase in median 28-day ventilator-free days and PICU-free days. Tracheostomy
(odds ratio 7.44) and prolonged MV (odds ratio 2.75) were independent variables signiﬁcantly associated
with VARI. A trend towards a reduction in PICU mortality was observed, from 28.4% to 16.6% (relative risk
0.58).
Conclusions: The implementation of a care bundle to prevent VARI in children had a different impact on
VAP and VAT, diminishing VAP rates and delaying VAT onset, resulting in reduced healthcare resource
use. Tracheostomized children were at increased risk of VARI, but preventive measures had a greater
impact on them.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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There has been growing interest in bringing down the rates of
ventilator-associated pneumonia (VAP) by applying the successful
multi-disciplinary approach for reducing central line-associated
bloodstream infections in intensive care units (ICUs).1,2 However,
as noted by Shahin et al.,3 most studies aimed at achieving a zero
VAP rate have excluded high-risk patients such as immunocom-
promised patients, patients already treated with antibiotics, and* Corresponding author.
E-mail address: jrello@crips.es (J. Rello).
http://dx.doi.org/10.1016/j.ijid.2016.09.021
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).patients on prolonged mechanical ventilation – even though the
latter are the most resource-intensive recipients of critical care,
and their morbidity and mortality rates are high.4 Ventilator-
associated tracheobronchitis (VAT) has also been independently
associated with adverse outcomes and has been identiﬁed as an
important source of PICU morbidity: it may in fact be more
prevalent than VAP in children and is likely to be a clinically
important nosocomial infection in its own right.5,6 Muszynski et al.
reported successful implementation of a care bundle to prevent
VAT in a paediatric ICU (PICU).7 However, it appears that the
simultaneous impact of the implementation of a ventilator care
bundle on VAP and VAT rates has not yet been assessed in children,
including patients undergoing prolonged mechanical ventilation.ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Y. Pen˜a-Lo´pez et al. / International Journal of Infectious Diseases 52 (2016) 43–4844Furthermore, the role of tracheostomy as a risk factor for VAP or
VAT in children has not been assessed either, since tracheostomy
for children admitted to the PICU is infrequent, related to previous
prolonged mechanical ventilation at home or performed late
following PICU admission, usually surgical.8
It was hypothesized that VAP and VAT are different. The
primary objective of this study was to evaluate whether the
implementation of a ventilator care bundle in the PICU could
simultaneously reduce the incidence of VAP and VAT in critically ill
children, including those on prolonged mechanical ventilation. The
primary outcome was the reduction in VAP and VAT rates, taking
into account the two airway devices (endotracheal and tracheos-
tomy tubes); the secondary outcome measures were ventilator-
free days, PICU-free days, and PICU mortality.
2. Materials and methods
2.1. Study design and setting
A prospective, pre- and post-intervention cohort study was
conducted in a 16-bed medical–surgical PICU of a 220-bed tertiary
care paediatric hospital, which serves as a referral centre for
transplant, burns, haemato-oncological, and immunocompro-
mised children, admitting patients from 1 week to 16 years of age.
The study was divided into three periods: (1) the pre-
intervention period (PI), from January 2010 to December 2010;
(2) the early post-intervention period (EP), from January 2011 to
December 2011; (3) the late post-intervention period (LP), from
January 2012 to December 2012.
2.2. Data collection and deﬁnitions
All children admitted to the PICU who had received invasive
mechanical ventilation (MV) for 48 h or longer were included.
There were no exclusion criteria. Cases of VAP or VAT were
recorded according to the US Centers for Disease Control and
Prevention (CDC) criteria.9,10 In brief, VAP was deﬁned as the
presence of a new or progressive and persistent pulmonary
inﬁltrate, consolidation, or cavitation (or pneumatoceles in those
aged 1 year) and at least three of the following, in a patient under
MV for 48 h:9 (1) temperature >38 8C or <36.5 8C with no other
recognized cause; (2) leukocyte count 12  109/l (15  109/l for
12 years old) or <4  109/l ; (3) new onset of purulent tracheal
secretions or change in character of sputum, or increased
respiratory secretions or increased suctioning requirements; (4)
new onset or worsening cough, or dyspnoea, apnoea, or
tachypnoea; (5) wheezing, rales, or bronchial breath sounds; (6)
worsening gas exchange, increased oxygen requirements, or
increased ventilator demand (mandatory point for infants 1
year old); and (7) bradycardia (<100 beats/min) or tachycardia
(>170 beats/min) (only for infants 1 year old). The diagnosis of
VAP was considered to be laboratory-conﬁrmed if either bronch-
oalveolar lavage or endotracheal aspirate cultures presented
signiﬁcant growth (>104 CFU or >105 CFU, respectively). VAT
was deﬁned on the basis of the absence of clinical and radiographic
evidence of pneumonia, the presence of a positive culture obtained
by deep tracheal aspirate, and at least two of the following signs in
a patient under MV for 48 h:9 fever >38 8C, cough, new or
increased purulent tracheal secretions, rhonchi, and wheezing (and/
or respiratory distress, apnoea, or bradycardia in infants 1 year
old). Ventilator-associated respiratory infection (VARI) included
VAP and VAT cases, as deﬁned elsewhere.11 The incidence rates of
VAP, VAT, and VARI were expressed as the cases of VAP, VAT, and
VARI per 1000 ventilator-days. Tracheostomy and endotracheal
VAP, VAT, and VARI incidence rates were also calculated, deﬁned as
cases of VAP, VAT, and VARI per 1000 tracheostomy-days on MV(tracheostomy ventilator-days) or endotracheal tube ventilator-
days, respectively.
Clinical and demographic information, including the Paediatric
Logistic Organ Dysfunction (PELOD) score,12 duration of MV, length
of stay, ventilator- and PICU-free days, and mortality were
recorded. Prolonged mechanical ventilation (PMV) was deﬁned
as the need for 21 consecutive days of MV for 6 h per day.13
This study was performed as part of the surveillance
programme for the prevention and control of nosocomial
infections at the authors’ centre. The need for individual informed
consent is waived for the practice of surveillance, prevention, and
infection control activities. The study was conducted in accordance
with the principles of the Declaration of Helsinki. Data for each
study subject were entered into a research database without
patient identiﬁers for analysis. The study was reviewed and
received ethical approval from the institutional review board.
2.3. Ventilator care bundle
A multidisciplinary team was convened to create a ventilator
care bundle, which was implemented in January 2011. The
ventilator care bundle consisted of ﬁve measures: (1) elevation
of the patient’s head from the bed to at least 30˚; (2) a structured
oral care protocol, including oral care with chlorhexidine solution
0.12% every 6 h and tooth brushing with a standard toothpaste
every 12 h; (3) use of cuffed endotracheal tubes when not
contraindicated; (4) maintenance of tracheal tube/tracheostomy
cuff pressure between 20 and 30 cmH2O; and (5) circuit changes
only if the circuit becomes soiled or damaged. In January 2012, a
new tracheostomy care protocol was added. Intervals between
tracheostomy tube changes increased from weekly to fortnightly,
and stoma care and disinfection of the tracheostomy cannula were
standardized.
All patients who underwent MV for >24 h received gastroin-
testinal bleeding prophylaxis. Selective digestive tract decontami-
nation was not performed and patients did not routinely receive
prophylactic antibiotics unless as surgical prophylaxis. An early,
targeted antibiotic therapy for VAT was prescribed.
2.4. Educational intervention
All healthcare workers in the PICU attended an educational
programme consisting of 2-h formal lectures, an educational
handout, and an evaluation test before the lectures. Notices were
periodically posted in the unit encouraging staff to continue
applying the measures and giving feedback on the ventilator-
associated infection rates. Surveys evaluating ICU staff knowledge
of evidence-based guidelines for the prevention of VAP were
administered twice during the study.
2.5. Statistical analysis
Descriptive data were recorded as frequencies and percentages
for categorical variables. Continuous variables were expressed as
the mean and standard deviation (SD) or median and interquartile
range (IQR), depending on whether the data were normally or non-
normally distributed. The incidence of overall VAP, VAT, and VARI
was calculated as the number of cases of VAP, VAT, and VARI per
1000 ventilator-days, either through tracheostomy or endotrache-
al tube. The incidence of tracheostomy VAP, VAT, and VARI was
calculated as the number of cases of VAP, VAT, and VARI per
1000 tracheostomy ventilator-days. Ventilator-free days and PICU
free-days at 28, 60, and 90 days were also calculated. All patients
who died in the PICU had zero PICU-free days and zero ventilator-
free days. Patients who were discharged on positive pressure
ventilation also had zero ventilator-free days. Patients with a
Table 1
Baseline characteristics of patients presenting in the pre-intervention period (2010)
and follow-up periods (2011 and 2012)
2010
(n = 95)
2011
(n = 109)
2012
(n =108)
Male sex, n (%) 55 (57.8%) 69 (63.3%) 61 (56.5%)
Age (years), mean (SD) 2.9 (4.19) 3.9 (5.09) 4.0 (5.10)
Diagnosis at admission, n (%)
Surgical pathology 37 (38.9%) 40 (36.7%) 39 (36.1%)
Medical pathology 58 (62.1%) 69 (63.3%) 69 (63.9%)
Pre-existing conditions, n (%)
Respiratory 4 (4.2%)a 8 (7.3%)a 18 (16.7%)a
Cardiovascular 40 (42.1%) 45 (41.3%) 38 (35.2%)
Neurological 3 (3.1%) 8 (7.3%) 8 (7.4%)
Renal/metabolic 2 (2.1%) 7 (6.4%) 3 (2.8%)
Gastrointestinal/liver 6 (6.3%) 8 (7.3%) 3 (2.8%)
Trauma 5 (5.3%) 1 (0.9%) 6 (5.5%)
Burn injury 2 (2.1%) 7 (6.4%) 3 (2.8%)
Immunocompromise 22 (23.1%) 17 (15.6%) 17 (15.7%)
None 21 (22.1%) 24 (22.0%) 23 (21.3%)
PELOD score, median (IQR) 13 (10–31) 13 (11–23) 12 (10.25–21)
Patients under ECMO, n (%) 2 (2.1%) 11 (10.1%) 9 (8.3%)
Patients with prolonged
mechanical ventilation, n (%)
13 (13.7%) 20 (18.3%) 25 (23.1%)
Patients with tracheostomy, n (%) 8 (8.4%) 11 (10.1%) 18 (16.7%)
SD, standard deviation; PELOD score, Paediatric Logistic Organ Dysfunction score;
IQR, interquartile range; ECMO, extracorporeal membrane oxygenation.
a p < 0.05.
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ventilator-free days, and patients requiring PMV were excluded
from the analyses of ventilator- and PICU-free days at 28 days.
To compare study periods between groups, a Pearson Chi-
square test or Fisher’s exact test was used for categorical variables
and the Mann–Whitney U-test for continuous variables. All tests
were two-tailed and a p-value of 0.05 was considered signiﬁcant.
To estimate the reduction in VAP, VAT, and VARI rates between the
pre- and late post-intervention periods, the relative risk (RR) and
95% conﬁdence interval (95% CI) were calculated. For MV and PICU
length of stay, as well as PICU- and ventilator-free days at 28, 60,
and 90 days, the change between periods was expressed by
calculating Hodges–Lehmann median differences and their 95% CI.
A stepwise logistic regression model, including variables that were
statistically signiﬁcant in the bivariate analysis, was performed to
identify independent predictors of VARI and mortality. Odds ratios
(OR) and 95% CI are reported.
All analyses were performed using STATA v. 13.0 (StataCorp LP,
College Station, TX, USA).
3. Results
During the study period, 312 patients (20.9%) out of 1490 ad-
mitted to the PICU underwent invasive MV for longer than 48 h. Of
these, 58 patients (18.5%) were ventilated for longer than 3 weeks
(PMV) and 37 were carrying a tracheostomy (11.9%). Of the
312 patients, 95 were admitted during the pre-intervention period,
109 during the early post-intervention period, and 108 during the
late post-intervention period. Table 1 shows the demographic and
patient characteristics. A statistically signiﬁcant difference be-
tween the pre- and late post-intervention periods was found only
for pre-existing respiratory conditions.
A total of 47 VARI episodes (14 VAP and 33 VAT) were
documented in 37 patients. Six patients developed two or more
episodes of VARI and three developed both VAP and VAT. No VAT
progressed to VAP. Thirty-two VARI episodes (68%) were
documented in PMV patients and 18 VARI episodes (38.3%) inTable 2
Ventilator-associated respiratory infection rates and outcomes in the pre-intervention 
2010 2011 
Invasive mechanical ventilation days 1451 1867 
Endotracheal ventilator days (rate) 961 (0.66) 1561 (0.8
Tracheostomy ventilator days (rate) 490 (0.34) 306 (0.16
Overall ratesa
VAP, episodes (rate) 6 (4.14) 5 (2.68) 
VAT, episodes (rate) 10 (6.89) 8 (4.12) 
VARI, episodes (rate) 16 (11.03) 13 (6.96) 
Endotracheal ratesb
VAP, episodes (rate) 2 (2.07) 4 (2.56) 
VAT, episodes (rate) 8 (8.30) 6 (3.84) 
VARI, episodes (rate) 10 (10.37) 10 (6.41) 
Tracheostomy ratesc
VAP, episodes (rate) 4 (8.16) 1 (3.27) 
VAT, episodes (rate) 2 (4.08) 2 (6.54) 
VARI, episodes (rate) 6 (12.24) 3 (9.8) 
Duration of mechanical ventilation (days), median (IQR) 7 (4–12) 7 (4–15) 
Ventilator-free days at 28 days 21 (8–24) 22 (16.5–
Ventilator-free days at 60 days 52.5 (0–55) 52 (36.25
Ventilator-free days at 90 days 82 (0–85) 82 (66.25
PICU length of stay (days), median (IQR) 11 (8–21) 14 (8–28)
PICU-free days at 28 days 15 (0–20) 15 (7.5–2
PICU-free days at 60 days 45 (0–52) 44 (5.25–
PICU-free days at 90 days 75 (0–82) 74 (32.75
PICU mortality, n (%) 27 (28.4%) 20 (18.3%
RR, relative risk; CI, conﬁdence interval; VAP, ventilator-associated pneumonia; VAT
infection; IQR, interquartile range; PICU, paediatric intensive care unit.
a Number of ventilator-associated VAP, VAT, or VARI per 1000 ventilator-days.
b Number of VAP, VAT, or VARI per 1000 endotracheal tube-days.
c Number of ventilator-associated VAP, VAT, or VARI per 1000 tracheostomy ventilapatients with a tracheostomy. Overall, endotracheal, and trache-
ostomy VAP, VAT, and VARI rates are detailed in Table 2 and
Figures 1 and 2. In the late post-intervention period, the overall
VAP rate fell by 74.7% from baseline, from 4.14 to 1.05 episodes per
1000 ventilator-days (RR 0.25, 95% CI 0.04–1.18), whereas the VAP
rate in tracheostomy-ventilated patients decreased from 8.16 to
0.65 cases per 1000 tracheostomy ventilator-days (RR 0.08, 95% CI
0.00–0.80). In contrast, the decline in VAT rates was not signiﬁcant,
either overall or in tracheostomized patients. A 2-day increase in
median ventilator-free days at 28 days and an increase of more
than 3 days in median PICU-free days at 28, 60, and 90 days(2010) and follow-up periods (2011 and 2012)
2012 RR or between-groups difference* (95% CI) p-Value
2869
4) 1332 (0.46) 0.701 (0.66–0.74) <0.001
) 1537 (0.54) 1.586 (1.46–1.72) <0.001
3 (1.05) 0.253 (0.041–1.184) 0.088
15 (5.23) 0.759 (0.319–1.888) 0.628
18 (6.27) 0.569 (0.274–1.193) 0.143
2 (1.50) 0.724 (0.052–9.984) 1.000
7 (5.26) 0.633 (0.195–1.998) 0.525
9 (6.76) 0.651 (0.234–1.784) 0.476
1 (0.65) 0.080 (0.002–0.805) 0.028
8 (5.23) 1.275 (0.254–12.327) 1.000
9 (5.86) 0.478 (0.152–1.633) 0.262
6.5 (4–17.5) 0.6646
24) 23 (19–25) 2.0 (0–3)* 0.0049
–56) 53 (21.75–56) 0.5 (0–2)* 0.1177
–86) 83 (50.5–86) 1.0 (0–2)* 0.1087
 9.5 (6–22.75) 0.1301
0) 19 (12.5–22.5) 4.0 (1–6)* 0.0006
52) 48.5 (17–54) 3.5 (0–5)* 0.0255
–82) 78.5 (47–84) 3.5 (0–5)* 0.0252
) 18 (16.7%) 0.586 (0.35–1.00) 0.062
, ventilator-associated tracheobronchitis; VARI, ventilator-associated respiratory
tor-days.
Figure 1. Overall ventilator-associated respiratory infection rates during the study
period. VARI, ventilator-associated respiratory infection; PI, pre-intervention
period; EP, early post-intervention period; LP, late post-intervention period.
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mortality fell from 28.4% to 16.6% (RR 0.58, 95% CI 0.35–1.00).
Comparing VAP with VAT, the only statistically signiﬁcant
differences found between the groups were age (mean 21.9 months
in VAT vs. 5 years in VAP; p = 0.009) and PICU mortality (17.4% in
VAT vs. 54.5% in VAP; p = 0.045). There were no differences in
tracheostomy, PMV, previous respiratory conditions, or ventilator-
and PICU-free days.
During the study period, the median time to the development of
VAT from the onset of MV or previous VARI increased signiﬁcantly
from 5.5 to 48 days (Table 3); however, this was not the case for
VAP. Crude PICU mortality after a VARI episode was 27.6%. Gram-
negative bacteria were the most common microorganisms isolated
(n = 31, 65.9%), with Pseudomonas aeruginosa and Stenotrophomo-
nas maltophilia predominating. Seven cases of VARI (14.8%) were
polymicrobial.
Comparing VARI to non-VARI patients (Supplementary Mate-
rial, Table S1), comorbidities were less frequent in patients who
did not develop a VARI. Male sex, immunocompromise, higher
PELOD, PMV, and tracheostomy were more frequent in VARI
patients than in non-VARI patients. In these patients, tracheostomyFigure 2. VAT and VAP rates: overall (a), tracheostomy (b), and endotracheal tube (c). VAT
pre-intervention period; EP, early post-intervention period; LP, late post-intervention (OR 7.44, 95% CI 2.8–19.6) and PMV (OR 2.75, 95% CI 1.04–7.25)
were the only independent risk factors associated with VARI. VARI
was also signiﬁcantly associated with higher mortality (35.1% vs.
16.4; p = 0.011). There were no statistically signiﬁcant differences
between groups in ventilator- and PICU-free days at 28 days, but at
both 60 and 90 days there was a difference of 31 days in favour of
the non-VARI group.
4. Discussion
This appears to be the ﬁrst published study assessing the
prevention of VAP and VAT after the implementation of a ventilator
care bundle in children, including patients on PMV. Interestingly,
the effect of the bundle on VAP and VAT was different. These
results highlight the differences in behaviour of each ventilator-
associated infection (VAT vs. VAP) according to the airway device
(endotracheal vs. tracheostomy tube) and other quality-of-care
indicators.
In recent years, the use of speciﬁc care bundles to control
infection in the ICU has been demonstrated to be effective. Like
catheter-related bloodstream infection rates, VAP rates have been
proposed as a measure of a hospital’s quality of care for critically ill
patients. This has generated debate regarding the absence of a gold
standard deﬁnition14,15 and the exclusion of PMV patients because
of the policy of discharging them to long-term care facilities.16
Furthermore, VAT is a more frequent condition in children than
VAP and is an important cause of morbidity and health resource
consumption,5–7 which is consistent with the present results.
However, VAT has only rarely been considered in these studies, as
have PMV patients, who are signiﬁcant consumers of healthcare
resources.4 Since the prevalence of PMV in the PICU is also rising
due to the increase in children with complex chronic conditions,17
it was decided to include these patients to give a more realistic
evaluation of the preventability of VARI in children.
During the study period, the number of patients with previous
respiratory diseases, overall ventilator-days, and tracheostomy
ventilator-days increased. Despite this rise in risk factors post-
intervention,18 it was possible to reduce the VAP rate after the
implementation of the ventilator care bundle. The overall impact of, ventilator-associated tracheobronchitis; VAP, ventilator-associated pneumonia; PI,
period. Dashed line = VAT rates; solid line = VAP rates.
Table 3
Median time to the development of a ventilator-associated respiratory infection from the onset of mechanical ventilation or previous episode, during the pre-intervention
period and the late post-intervention period.a
2010
Pre-intervention period
2012
Late post-intervention period
Between-groups difference (95% CI) p-Value
Onset
VAP 27 (9–56) 19 (4–115) 8 (76 to 104) 1
VAT 5.5 (2–11.5) 48 (24–93) 42.5 (3 to 65) 0.004
VARI 10.5 (3.25–32.5) 43.5 (15.5–93.5) 33 (1 to 65) 0.016
CI, conﬁdence interval; VAP, ventilator-associated pneumonia; VAT, ventilator-associated tracheobronchitis; VARI, ventilator-associated respiratory infection.
a Data are presented as the median (interquartile range).
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among tracheostomized patients, who represented only 11.9% of
the population studied and 37.7% of MV days. Among these
patients, VAP decreased by 60% after the introduction of the
ventilator bundle and by a further 81% after the introduction of
standardized stoma care and disinfection of the cannula. In
contrast, VAP rates decreased by only 28% in patients ventilated
through endotracheal tubes (275 of 312 patients, corresponding to
62.3% of MV days). This is well reﬂected in the fact that
tracheostomy was found to be one of the signiﬁcant factors
associated with the development of a respiratory infection (OR
7.44, 95% CI 2.8–19.6). Until now, the role of tracheostomy as a risk
factor for VAP or VAT in children has not been assessed and these
are interesting data that suggest that tracheostomized children are
at increased risk of ventilator respiratory infections, but that
preventive measures may have a greater impact on them.
The fact that the closing of the vocal cords is preserved in most
children undergoing tracheostomy, along with the difﬁculty in
maintaining 30˚ to 45˚ head-of-bed elevation for small paediatric
patients,19 could explain the lower effectiveness of the bundle on
the endotracheal tube VAP rates.
Interestingly, each of the VARI responded differently to the
bundle. Both endotracheal and tracheostomy VAT rates failed to
decrease signiﬁcantly. These results are in contrast with those of
Muszynski et al., who reported a statistically signiﬁcant decrease in
VAT rates after the implementation of a ventilator care bundle for
preventing VAT in a PICU, although they did not include speciﬁc
items for VAT.7 The children on PMV included in the present study
may explain these differences: 68% of VARI in the present series
developed in patients on PMV, while the upper interquartile range
of the duration of MV reported by these authors in their post-
intervention period was 8.6 days. Applying a ventilator care bundle
was not sufﬁcient to signiﬁcantly reduce VAT in the present study
population; however, it was possible to delay the onset of VAT by
42.5 days. Thus, complete elimination of VAP and even VAT may be
an unrealistic goal in a major referral hospital caring for complex
patients on PMV.9,20,21 As pointed out by Klompas, we need to
consider other indicators to establish the effectiveness of the
ventilator care bundle, especially in these patients.15 Interestingly,
the time to onset of VAP did not change signiﬁcantly, whereas the
time to onset of VAT was greatly delayed. These data suggest a
different pathophysiology in VAP compared to VAT.22 No VAP
developed in patients presenting VAT, in agreement with current
pathophysiological concepts that the treatment of VAT may
effectively prevent VAP.23
The increase in median ventilator-free days and PICU-free days
over the study period is also interesting, showing that the
ventilator care bundle not only contributed to improved quality
of care, but was also cost-saving. Considering only the cost of 1 day
in the ICU (1500 Euro according to Spanish data),20 a saving of
6000 Euro per patient and an overall saving of 648 000 Euro in days
of PICU stay during the late post-intervention period was
estimated. The lack of improvement in ventilator-free days at60 and 90 days despite the increase in PICU-free days at 60 and
90 days was probably due to the fact that most PMV patients were
discharged on MV. These patients, characterized by a higher
burden of chronic conditions and a markedly prolonged stay, have
a higher risk of VARI than others, as was shown in the present
cohort and in agreement with some previous reports.3,14,21 On the
other hand, Chelluri et al. showed that while the severity of illness
is the primary risk factor for death within the ﬁrst 14 days of ICU
admission, comorbidities are among the primary risk factors after
14 days.24 According to the results of the present study, VARI may
contribute to this. During this study, although PELOD scores were
similar in the pre-intervention and post-intervention periods,
overall PICU mortality dropped from 28.4% to 16.6%.
This study has several limitations. First, it was a quasi-
experimental study, with a level of evidence lower than a
randomized trial. The current deﬁnitions of VAP and VAT are
subject to a lack of a gold standard, but they are those used by the
majority of authors. Second, adherence to the bundle was not
assessed, and ﬁndings might be different for other adherence
rates. Some confounding clinical practices were not standardized
during the study period, such as sedation, tracheostomy timing,
and PICU discharge criteria, thereby limiting generalization. It is
therefore possible that observed changes were caused by pre-
existing secular trends or secondary to initiatives unrelated to the
intervention. However, the analyses were adjusted using detailed
patient-level data including age, sex, pre-existing conditions, and
PELOD score. Furthermore, even if the effect on VAP and VAT was
caused by something other than the intervention, the primary
goal of this study was to assess the preventability of VAT and VAP
when including children on PMV, rather than to test the
effectiveness of the bundle per se. Additionally, this was a
single-centre study, thus the results cannot be extrapolated to
cohorts with a different case mix. Future research should focus on
VARI instead of only VAP and should not be limited to low-risk
children, but should also include tracheostomized children and
those on PMV.
In conclusion, this ﬁrst prospective analysis of the preventabil-
ity of ventilator-associated infections in children, including those
on PMV, showed that the implementation of a ventilator care
bundle had different effects on VAP and VAT, diminishing VAP
rates and delaying VAT onset. Furthermore, it resulted in a reduced
healthcare resource use. The effect also was different depending on
the airway device. Tracheostomized children were at increased risk
of ventilator respiratory infections, but preventive measures had a
greater impact on them.
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